Michael Ulz
Morgan Stanley, Research Division
All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I’m Mike Ulz, one of the biotech analysts here. It’s my pleasure to introduce the team from Dyne Therapeutics. To my immediate left John Cox, President and CEO; and to his left is Erick Lucera, CFO. And just a reminder, the format for today is a fireside chat. But if anyone in the audience has a question, you can raise your hand, and we’ll try and get it addressed during our discussion.
But before we get started, I just need to read a quick disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.
And with that, I’ll hand it over to John to make some introductory comments before we jump into Q&A.
John Cox
CEO, President & Director
Terrific. Thanks, Mike. Well, I’ll just mention a little bit about where we are at Dyne right now. It’s an incredibly exciting time for us. This company over the last couple of years has been preparing for the moment right in front of us, which is to launch a very important medicine in DMD. And that’s early next year, followed by DM1 the following year.
So we’ve been building a — I guess I’d describe it as a pure-play neuromuscular stand-alone, fully integrated biotech. Over the last 1.5 years, we have built out our
Credit: Source link
